Panitumumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Panitumumab: From Metastatic Colon Cancer to Drug-Induced Osteoporosis
One-Sentence Summary
Panitumumab is an anti-EGFR monoclonal antibody originally used for metastatic colon cancer. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Metastatic malignant neoplasm of the colon (from the knowledge graph; the Singapore licence record contains no indication text) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.13% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Panitumumab is known to be an anti-EGFR monoclonal antibody, and its efficacy in metastatic colon cancer is the basis of its original use.
EGFR signalling plays a role in osteoblast differentiation and bone remodelling, so a theoretical link to bone metabolism exists. However, the likely direction of effect is unfavourable: EGFR blockade is more likely to impair bone formation. Panitumumab is also associated with hypomagnesaemia and hypocalcaemia, which could worsen bone health. The high TxGNN score is a graph-based prediction only, and the mechanism does not clearly support benefit.
Other top-ranked predictions are mostly eye conditions (diabetic retinopathy and several types of cataract), all at L5 with no trials or literature. Their rationale is weak or contradictory. For example, tetanic cataract is caused by low calcium, which panitumumab can itself lower. Anti-EGFR antibodies also cause known ocular toxicities (keratitis, conjunctivitis), and a large intravenous antibody is not expected to penetrate the eye well.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14498P | Vectibix Concentrate for Solution for Infusion 100 mg/vial (Amgen Manufacturing Limited LLC) | Infusion, solution concentrate | Not stated in the licence record |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (anti-EGFR monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Electrolytes (magnesium, calcium) are relevant given the known effects; please refer to the package insert for the full list |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 27 interactions were identified in total. Those listed include:
- Major: amiodarone, arsenic trioxide, bevacizumab, dofetilide, dronedarone, droperidol, irinotecan (including liposomal), levacetylmethadol, aminolevulinic acid
- Moderate: proton pump inhibitors (rabeprazole, omeprazole, dexlansoprazole, esomeprazole, lansoprazole, pantoprazole), methoxsalen, topical aminolevulinic acid, disopyramide, idelalisib
- Class-related effects noted in the mechanistic review: hypomagnesaemia, hypocalcaemia, and ocular toxicities (keratitis, ulcerative keratitis, conjunctivitis).
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no trials or literature (L5). The mechanistic review suggests EGFR blockade and panitumumab's calcium and magnesium effects could worsen rather than improve bone health. The same applies to the other predicted indications.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, so safety screening can be done
- Mechanism of action data from DrugBank
- Preclinical or observational evidence on EGFR inhibition and bone metabolism, including the direction of effect
- Review of the benefit-risk balance of a systemic oncology biologic for a non-oncology bone indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.